SEC For	rm 4 FORM	4 U	INITE	D STAT	'ES S	SEC	URITIE	S AN	DE	XCHAN	IGE C	OM	NISSIC	N			
					Washington, D.C. 20549											DVAL	
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).					Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940									Estim	Number: nated average bur s per response:	3235-0287 den 0.5	
1. Name and Address of Reporting Person [*] KARBE FRANK					2. Issuer Name and Ticker or Trading Symbol <u>Better Therapeutics, Inc.</u> [BTTX]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
(Last) C/O BE	``	(First) (Middle) R THERAPEUTICS, INC.			3. Date of Earliest Transaction (Month/Day/Year) 04/10/2023								X Officer (give title Other (specify below) below) See Remarks				
548 MARKET STREET, #49404					4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street) SAN FRANCISCO CA 94104				X Form filed by One Reporting Person Form filed by More than One Repo													
(City) (State) (Zip)				Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													
		Table	e I - No	n-Deriva	tive S	Secu	rities Acq	uired	, Dis	posed of	, or Bei	nefici	ally Owr	ned			
Date			Date	2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		ction Instr.	4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)			nd Secur Benet Owne	icially d Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership		
								Code	v	Amount	(A) or (D)	Price	Repo Trans (Instr	action(s) 3 and 4)		(Instr. 4)	
Common Stock 04/10/2				.023			P ⁽¹⁾		242,424	Α	\$0.8	25 2	92,424	D			
		Ta	ble II -							osed of, o convertibl				d			
1. Title of Derivative Security (Instr. 3)	Derivative Conversion Date Execution Security or Exercise (Month/Day/Year) if any					5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	Expira vative (Month urities uired or oosed)) ir. 3, 4			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	ly Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownershi (Instr. 4)		

Explanation of Responses:

1. On April 6, 2023, the Issuer entered into a Securities Purchase Agreement with certain investors (the "PIPE Investors") in a private placement offering, pursuant to which the PIPE Investors agreed to purchase shares of Issuer common stock for \$0.825 per share. As one of the PIPE Investors, the Reporting Person acquired 242,424 shares of Issuer common stock on April 10, 2023 for \$0.825 per share.

Date Exercisable Expiration Date

Remarks:

Chief Executive Officer, President, Treasurer and Secretary

<u>/s/ Mark Heinen, Attorney-in-</u>	04/12/2023
Fact	04/12/2023

** Signature of Reporting Person Date

Amount or Number

of Shares

Title

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

v

Code

(A) (D)

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.